Virtual BDD 2021 - E-posters
All posters have a link to a PDF for more detailed viewing, and in most cases also a link to a recorded video by the author.
Progressive and sustained improvements in the extent and severity of atopic dermatitis with tralokinumab in combination with topical corticosteroids as needed in moderate-to-severe atopic dermatitis (Submitted by Leo Pharma).
Results from the open-label treatment period of a long-term proactive management phase III trial using fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam (submitted by Leo Pharma).
Long-term proactive management of psoriasis vulgaris with fixed-dose
combination of calcipotriene 0.005% and betamethasone dipropionate
0.064% foam: results of a Phase III randomized controlled trial (submitted by Leo Pharma).
Safety of specifically targeting interleukin-13 with tralokinumab in adult
patients with moderate-to-severe atopic dermatitis: pooled analysis of five
randomised, double-blind, placebo-controlled Phase 3 and Phase 2 trials (Submitted by Leo Pharma).
Impact of Baricitinib in Combination with Topical Corticosteroids on
Patient-Reported Outcomes in Adult Patients with Moderate-to-Severe
Atopic Dermatitis: Measures of Atopic Dermatitis Symptoms and
Quality of Life from BREEZE-AD4 and BREEZE-AD7 Phase 3 Trials (Submitted by Eva Moelants - Lilly).
Watch the video